CClinicalTrials.gg
Sign In
CompletedNCT00509977Updated Dec 3, 2021

Study of Light Treatment and Laser Treatment for Melasma

An interventional study of Light Treatment and Laser Treatment in Melasma, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Read the detailed description

The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

02

Conditions studied

  • Melasma

Browse trials for

03

In context

Melanosis

149 studies on the registry are indexed under Melanosis; 38 are open to participants now.

This study's enrollment of 17 is below the median of 40 across 139 interventional studies indexed under Melanosis.

Browse Melanosis studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of melasma lesion measuring at least 4 square centimeters.
  • Age 18-75 years.
  • Good health.
  • Willingness and ability to understand and provide informed consent for participation in the study.
  • Ability to communicate with the investigator.
  • Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the protocol or to give informed consent.
  • Mental illness.
  • Under 18 years of age and over 75 years of age.
  • Laser treatment in the last 6 months before enrollment.
  • Isotretinoin within the past year.
  • Lidocaine allergy.
  • History of herpes simplex viral infection.
  • Concurrent active disease to facial area (i.e acne).
  • Bleeding disorder.
  • History of abnormal wound healing.
  • History of abnormal scarring.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    Light therapy

    Procedure: Light Treatment

  • Experimental
    2

    Laser Treatment

    Procedure: Laser Treatment

Interventions

  • ProcedureLight Treatment

    Light treatment applied to half of the face at each study visit

  • ProcedureLaser Treatment

    Laser treatment applied to half of the face at each study visit

06

What researchers measure

Primary outcomes

  1. Melasma Area and Severity Index

    Time frame: 20 weeks

Secondary outcomes

  1. Safety

    Time frame: 20 weeks

07

Study locations

1 site
  • Northwestern University Feinberg School of Medicine, Department of Dermatology
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Collyer J, Boone SL, White LE, Rademaker A, West DP, Anderson K, Kim NA, Smith S, Yoo S, Alam M. Comparison of treatment of cherry angiomata with pulsed-dye laser, potassium titanyl phosphate laser, and electrodesiccation: a randomized controlled trial. Arch Dermatol. 2010 Jan;146(1):33-7. doi: 10.1001/archdermatol.2009.318. PubMed 20083690 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00509977
Lead sponsor
Northwestern University
Responsible party
Murad Alam (Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation, Northwestern University) — Principal investigator
First posted
Aug 1, 2007
Start date
Apr 2007
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Dec 3, 2021

Study contacts

Murad Alam, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Melanosis→

Other studies from this sponsor

Northwestern University

Start the discussion